GlassScriptPhysician profile
Augustine Paul Hong
NPI 1457730863
$1,186.42
in general payments reported to CMS, 2019-2025
12 companies · $304 in 2025
The $304 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $163 · 2021: $155 · 2022: $86.18 · 2023: $260 · 2024: $94.64 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $605 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.97 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $518.41 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Beigene USA, INC. | $134.90 | 2023 | Brukinsa |
| Amgen INC. | $104.96 | 2021 | |
| Pfizer INC. | $94.64 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $86.18 | 2022 | |
| Astellas Pharma US INC | $65.40 | 2019-2020 | |
| Genentech USA, INC. | $53.45 | 2025 | |
| Genzyme Corporation | $40.89 | 2019 | |
| Janssen Biotech, INC. | $34.45 | 2021 | |
| Puma Biotechnology, INC. | $19.29 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.51 | 2019 | |
| Seagen INC. | $15.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Augustine Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.